[Application of activated recombinant factor VII (rFVIIa, NovoSeven) in neonatology].
Recombinant activated factor VII is vitamin K dependent glycoprotein, similar as the same in the human blood plasma. First has been described in application for hemophilia, where are presented inhibitors of factors VIII and IX, later was proved that it has effectiveness in hemorrhage with different etiology. Clinical experience with this medicine in neonatology is still small, but in the latest years there is some data about its effectiveness in hemorrhage in term and preterm newborns. The data shows that there is low risk of side effects of the recombinant activated factor VII in neonatal period. But still has been described as a experimental treatment.